The Technical Analyst
10X Genomics Inc [TXG]
Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
10X Genomics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.50% $27.80
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 327.64 mill |
| EPS: | -2.18 |
| P/E: | -12.75 |
| Earnings Date: | Apr 30, 2024 |
| SharesOutstanding: | 119.70 mill |
| Avg Daily Volume: | 1.403 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -12.75 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -12.75 | industry: PE -4.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 26.14 - 29.46 ( +/- 5.99%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-21 | Saxonov Serge | Buy | 88 854 | Class A Common Stock |
| 2024-03-21 | Hindson Benjamin J. | Buy | 71 083 | Class A Common Stock |
| 2024-03-21 | Mcanear Justin J. | Buy | 53 312 | Class A Common Stock |
| 2024-03-14 | Saxonov Serge | Sell | 1 086 | Class A Common Stock |
| 2024-03-04 | Saxonov Serge | Sell | 4 660 | Class A Common Stock |
| INSIDER POWER |
|---|
| 5.11 |
| Last 100 transactions |
| Buy: 4 660 285 | Sell: 4 260 557 |
Forecast:
16:00 - $28.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $28.00
Forecast 2: 16:00 - $28.00
Forecast 3: 16:00 - $28.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $27.80 (-0.50% ) |
| Volume | 1.728 mill |
| Avg. Vol. | 1.403 mill |
| % of Avg. Vol | 123.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TXG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $48.50 | N/A | Active |
|---|
TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-10 16:05:00 - Press Release
10x Genomics To Report First Quarter 2024 Financial Results On April 30, 2024
Pleasanton, calif. , april 10, 2024 /prnewswire/ -- 10x genomics, inc. (nasdaq: txg), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended march 31, 2024 after market close on tuesday, april 30, 2024.
2024-03-26 09:00:00 - Press Release
10x Genomics Commercially Launches Visium Hd Spatial Gene Expression Assay
Began global shipments for visium hd, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution pleasanton, calif. , march 26, 2024 /prnewswire/ -- 10x genomics, inc. (nasdaq: txg), a leader in single cell and spatial biology, announced today the commercial availability of its visium hd spatial gene expression product.
2024-03-21 16:05:00 - Press Release
10x Genomics Expands Xenium Menu With Multi-modal Cell Segmentation Kit And Immuno-oncology Gene Panel
Begins commercial shipments of xenium cell segmentation kit to improve determination of cell boundaries launches first xenium application-focused panel optimized for immuno-oncology across all tissue types pleasanton, calif., march 21, 2024 /prnewswire/ -- 10x genomics, inc. (nasdaq: txg), a leader in single cell and spatial biology, announced today the commercial availability of its xenium multi-modal cell segmentation kit and the launch of a new xenium gene panel optimized for immuno-oncology applications.
2024-03-13 16:05:00 - Press Release
10x Genomics Begins Commercial Shipments Of Chromium Gem-x Products
The next generation of the company's leading single cell technology architecture, gem-x, enables higher performance at larger scale and lower cost pleasanton, calif. , march 13, 2024 /prnewswire/ -- 10x genomics, inc. (nasdaq: txg), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the gem-x technology architecture, chromium single cell gene expression 3' v4 and chromium single cell immune profiling 5' v3.
2024-03-13 08:00:00 - Press Release
Vizgen Announces Denial Of 10x Genomics' Petition For Inter Partes Review Of Vizgen-licensed Patent Currently Asserted Against 10x's Xenium Platform
Cambridge, mass.--(business wire)--vizgen announces the denial of 10x genomics' petition for inter partes review of the vizgen-licensed patent asserted against 10x's xenium platform.
Latest News
2024-04-22 13:01:27 - Zacks Investment Research
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-03-01 14:00:57 - InvestorPlace
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.
2024-02-27 11:55:00 - The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.
2024-02-15 23:55:27 - Seeking Alpha
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript
2024-02-15 19:01:24 - Zacks Investment Research
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-02-15 18:21:07 - Zacks Investment Research
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.15 per share a year ago.
2024-02-08 11:05:45 - Zacks Investment Research
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-01-20 06:55:00 - Seeking Alpha
10x Genomics: Still Waiting For Entry
10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform, Xenium, which offers exceptional vision and surpasses competitors in speed, sensitivity, and specificity. 10x Genomics is poised for sustained growth with its pursuit of scientific advancements, expanding applications in various fields, and strategic partnerships.
2023-11-04 01:02:01 - Seeking Alpha
10x Genomics: Unveiling The Investment Potential
10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company has a huge growth opportunity in the genomics market thanks to its razor-blade business model and innovative product roadmap.
2023-11-02 23:27:08 - Seeking Alpha
10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Arias - Stifel Kyle Mikson - Canaccord Genuity Dan Brennan - TD Cowen Salem Salem - Barclays Tejas Savant - Morgan Stanley John Sourbeer - UBS Mason Carrico - Stephens Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Rachel Vatnsdal - JPMorgan Operator Thank you for standing by. My name is Aaron, and I will be your conference operator for today.